What's the best way to monitor low-risk patients with a history of differentiated thyroid cancer? by Albrecht, Angela M. et al.
Evidence-based answers from the  
Family Physicians Inquiries Network
jFPoNlINE.com Vol 58, No 12  |  DEcEmbEr 2009  |  ThE jourNal oF FamIly PracTIcE
rum Tg is adequate to follow-up low-risk 
patients. This test replaces the previous accept-
ed standard of thyroid hormone withdrawal 
(THW)-stimulated measurements. Moreover, 
rhTSH-stimulated serum Tg is comparable to 
a THW-stimulated measurement for detect-
ing recurrent disease, when a cutoff value of 
2 mcg/L is used.2
rhTSH testing has similar  
sensitivity to THW
A 2004 meta-analysis examined 46 studies 
with a total of 9094 patients. THW-stimulated 
Tg measurements after thyroid remnant abla-
tion had a sensitivity of 96% (95% confidence 
interval [CI], 93.5%-98.7%) and a specificity of 
94% (95% CI, 93.3%-96.1%). For rhTSH-stimu-
lated serum Tg measurements, sensitivity and 
specificity were 92% (95% CI, 88.9%-96.1%) 
and 88% (95% CI, 85.4%-90.6%), respectively. 
Because the difference in sensitivity be-
tween THW-stimulated and rhTSH-stimulated 
serum Tg isn’t statistically significant, rhTSH 
can be used for Tg testing without significantly 
decreasing detection of DTC recurrence. The 
slightly lower specificity of rhTSH may lead to 
unnecessary additional testing because of a 
few more false-positive results. However, this 
risk should be weighed against the benefits of 
reducing morbidity by avoiding the need to 
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Evidence summary
An estimated 37,340 new cases of thyroid 
cancer are diagnosed annually in the United 
States, typically in people between 20 and 55 
years of age. The most common type of thyroid 
cancer is DTC, which includes papillary and 
follicular carcinoma. Papillary carcinoma ac-
counts for 80% of all thyroid cancers, and fol-
licular carcinoma accounts for 10%. 
The 5-year survival rate for all cases of 
DTC is 97%. Although the disease has a favor-
able prognosis, an estimated 1630 patients 
were expected to die of it in 2009 because of 
its prevalence.1 
The goal: Find recurrent disease early
The purpose of surveillance protocols in thy-
roid cancer is early detection of recurrent dis-
ease. Expert debate about DTC surveillance 
centers on the disease’s low incidence and 
prolonged clinical course, as well as a lack of 
prospective randomized clinical trials. Cur-
rent guidelines were developed from large ret-
rospective cohort studies of patients observed 
over several decades. 
rhTSH-stimulated Tg  
is the new surveillance standard
All major professional organizations support 
the consensus that an rhTSH-stimulated se-
EvidEncE-basEd answEr
A recombinant human thyrotropin  (rhTSH)-stimulated serum thyro-
globulin (Tg) level alone is sufficient to 
monitor for recurrent disease in low-risk 
patients with a history of differentiated 
thyroid cancer (DTC) (strength of recom-
mendation [SOR] A, meta-analysis). Low-
risk patients are defined as patients who 
have undergone total thyroidectomy and 
radioactive iodine (I131) remnant ablation 
therapy and show no clinical evidence of 
recurrent disease. 
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withhold thyroid hormone replacement ther-
apy before testing.3
Thyroglobulin measurements:  
How they compare to body scanning
A 1999 prospective cohort study of 229 pa-
tients with DTC compared the accuracy of I131 
whole body scanning with serum Tg measure-
ment after both rhTSH and THW stimulation 
(TABlE). The results of the whole body scan 
were concordant with the rhTSH-stimulated 
and THW-stimulated Tg measurements in 
89% of the patients (P=.108). 
Using a cutoff value of ≥2 mcg/L for recur-
rent disease, an elevated Tg level was detected 
in 52% of patients with localized thyroid bed 
disease after rhTSH stimulation and in 56% of 
patients after THW stimulation. An elevated Tg 
level after rhTSH stimulation was found in 100% 
of patients with metastatic disease. Symptoms 
of hypothyroidism, including overall quality-
of-life scores, were significantly better in the 
rhTSH group than the THW group (P<.01).4
rhTSH-stimulated Tg: 
Accuracy with a lower cost
A retrospective cohort study of 107 patients 
determined that rhTSH-stimulated serum 
Tg levels alone are sensitive enough to iden-
tify recurrent disease in low-risk patients. 
Levels greater than 2 mcg/L had a sensitivity 
and negative predictive value of 100% and a 
false-positive rate of 9%—a statistically and 
clinically significant improvement in accuracy 
over a whole body scan obtained after rhTSH 
stimulation, which had a sensitivity of only 
27%, negative predictive value of 92%, and 
false-positive rate of 9% (P<.05). In low-risk 
patients, rhTSH-stimulated serum Tg mea-
surement is the most accurate and least costly 
method of surveillance because of its high 
negative predictive value.5 
Whole body scanning 
doesn’t enhance surveillance accuracy
This conclusion is supported by a cohort study 
that prospectively followed 99 patients with 
a history of DTC who underwent serum Tg 
measurement and an I131 whole body scan ob-
tained after rhTSH stimulation and were fol-
lowed by neck ultrasound 6 to 12 months after 
ablation treatment. The whole body scan was 
negative in 95% of the patients, with a sensitiv-
ity of 0%. Serum Tg was positive in 19 of these 
patients. Neck ultrasound confirmed positive 
lymph nodes in 7 patients, of whom 5 were 
Tg-positive. The I131 whole body scan added no 
benefit to the accuracy of surveillance.6 
TABlE
How surveillance strategies for low-risk patients compare
Protocol methodology outcomes benefit
THW-stimulated 
serum Tg level
Stop thyroid hormone 
 replacement 
after 14-28 days, ensure 
that TSh is ≥25 mu/l
obtain a Tg level and  
consider an I131 WbS
restart thyroid  
hormone replacement
Negative predictive value  
for recurrent disease 100% 
for Tg levels <2 mcg/l
I131 WbS unnecessary  
unless Tg levels are elevated
lower cost
rhTSH-stimulated 
serum Tg level
administer 0.9 mg rhTSh Im  
on day 0 and day 1
on day 4, obtain a Tg level 
and consider an I131 WbS 
continue thyroid  
hormone replacement
Negative predictive value  
for recurrent disease 100% 
for Tg levels <2 mcg/l 
I131 WbS unnecessary  
unless Tg levels are elevated
Improved quality-of-life measures 
compared with ThW group 
rhTSh, recombinant human thyrotropin; Tg, thyroglobulin; ThW, thyroid hormone withdrawal; WbS, whole body scan.
Adapted from: haugen br et al. J Clin Endocrinol Metab. 1999.4
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Recommendations
The British Thyroid Association and the Amer-
ican Thyroid Association recommend per-
forming a physical examination with serum 
TSH, Tg, and antithyroglobulin antibodies at 
6 and 12 months postablation, then annually 
if the patient is disease free.7,8 
In low-risk patients, stimulated serum 
Tg measurement alone is an acceptable ini-
tial follow-up; a value of ≥2 mcg/L indicates 
a need for further evaluation. If serum Tg is 
undetectable under TSH stimulation, subse-
quent long-term follow-up by serum Tg levels 
alone while under TSH suppression is suf-
ficient. TSH stimulation can be achieved by 
THW or rhTSH.7-9
A whole body scan rarely adds valuable 
additional information. Periodic neck ultra-
sound should be performed, however.7-9 
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